DAWN - NASDAQ

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%

HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.22B

EPS-1.0400

P/E Ratio-20.70

Earnings Date05/13/2026

dawn

Total Liabilities

Last Annual Value

66.67M

3-Year CAGR

58%

5-Year CAGR

98%

10-Year CAGR

Adjust for Inflation

Day One Biopharmaceuticals, Inc. Competitors Analysis of Total Liabilities

DAWN · NASDAQ

Company	Total Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	66.67M	31.2%	50.4%	N/A
Geron Corporation NASDAQ:GERN	344.67M	33.1%	28.2%	45.9%
Astria Therapeutics, Inc. NASDAQ:ATXS	23.10M	26.0%	34.7%	7.6%
Tyra Biosciences, Inc. NASDAQ:TYRA	23.43M	2.8%	36.4%	N/A
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	25.95M	30.0%	70.2%	N/A
Arvinas, Inc. NASDAQ:ARVN	284.00M	-23.9%	-18.7%	35.2%
Erasca, Inc. NASDAQ:ERAS	70.98M	-3.3%	9.6%	N/A
Vir Biotechnology, Inc. NASDAQ:VIR	237.55M	-10.3%	-14.6%	N/A
Replimune Group, Inc. NASDAQ:REPL	135.49M	14.1%	25.0%	N/A
Rezolute, Inc. NASDAQ:RZLT	13.36M	21.0%	-4.1%	20.2%

Day One Biopharmaceuticals, Inc. Fair Value Envelope

DAWN · NASDAQ

Our analysis suggests that DAWN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.53, this represents a potential HIDDEN relative to our calculated worth for Day One Biopharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $21.53

Related Guides

Blog Categories

Continue your DAWN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.